Biogen, Ionis End ALS Program; Ionis Will Advance Angelman Asset Alone

Long-Time Partners Decide Fate Of Two Drugs

 
• By Mandy Jackson
Illustration of abstract neuron on a blue background
Ionis will bolster its in-house neurology portfolio with wholly-owned ION582 • Source: Shutterstock

More from Clinical Trials

More from R&D